DiaCarta is a leading precision diagnostic company specializing in providing comprehensive one-stop-shop for cancer patient management solutions.
Our team of world-class scientists, clinicians, and industry experts is dedicated to advancing precision medicine through continued investment in research and development, strategic partnerships, and global expansion.
ISO 13485 certified GMP manufacturing facility
Based in California, USA, with global subsidiaries in Europe and Asia
Innovative R&D lab
CAP-accredited CLIA lab
Affordable Excellence with Unmatched Sensitivity and Specificity
Current genomics technology has improved a lot. We can now detect genetic/somatic mutations in tissue samples (biopsy) and even in body fluids (liquid biopsy). Still, it is tough to find rare genetic changes, especially those in early-stage cancer or residual cancer cells (MRD, or Molecular Residual Disease, monitoring).
XNA technology solves this problem by boosting sensitivity and specificity in traditional platforms like Sanger sequencing, qPCR, ddPCR, and NGS, without changing the existing protocol.
High-throughput and sensitive mutation detection and quantification capability without DNA sequencing
Tools like qPCR and ddPCR are often used to quantify gene copy number and gene expression. But, to get accurate results, we first need to extract and purify the DNA or RNA from samples. The problem is, during the extraction, we will lose some DNA or RNA. This becomes a big concern when we only have a small amount of samples to start with.
isobDNA™ technology solves the problem because it does require the sample extraction process. Instead of amplifying the targets like PCR technology, isobDNA technology amplifies the signals. It’s just as sensitive as PCR but more accurate.
DiaCarta and HMC/HML Team up for Customizing Lab Development Test Validations and Compliances in the US Market
DiaCarta announced that the company has formed strategic partnership with Hopkins MedTech Compliance and Hopkins MedTech Lab Services.
DiaCarta, Ltd. (“DiaCarta”), a precision molecular diagnostics company, today announced the termination of its Business Combination Agreement with HH&L Acquisition Co.
Influenza and COVID-19: what are they in common? Currently, the two most important respiratory viruses the healthcare authority is paying attention to are SARS-COV-2 (causing COVID-19) and influenza A and B viruses (Flu A and B). The Flu A and B viruses (named by the...
Cancer deaths due to failure of early detection According to the American Cancer Society researchers, it is estimated that there will be more than 600,000 people die of cancer, and 1.9 million new cancer cases in the US in 2021 alone. Seventy-one percent of the...